Michael Scannell

Michael Scannell is the Vice President of Chemistry and CMC at Longboard Pharmaceuticals, where responsibilities include overseeing chemistry and CMC development since January 2022. Previously held roles include Sr. Director of CMC Development at Esperion and Director of Analytical Development at QED Therapeutics, alongside significant contributions to United Therapeutics as Senior Director of Analytical Sciences. Michael has extensive experience in developing analytical and bioanalytical methodologies, regulatory agency interactions, and providing expert recommendations on CMC-related regulatory issues. Educational background includes a Ph.D. in Chemistry from the University of Maryland and a Bachelor's degree in Chemistry from Towson University.